Search - tctmd.com

Displaying 41 - 60 of 84

Sort: Relevancy | Date

Presentation TCT 2017

Topic 4: At the Cusp of Diminishing Returns for CV Therapies - Personalized Approaches and New Frontiers

Presenter: Robert A. Byrne, Gregg W. Stone, Robert A. Harrington

October 30, 2017

Presentation TCT 2017

Topic 3: Chronic Total Occlusion PCI - What Level of Evidence Is Required for Widespread Acceptance: Hard Endpoints vs QOL Measures

Presenter: Robert A. Byrne, Gregg W. Stone, J. Aaron Grantham

October 30, 2017

Presentation TCT 2017

Topic 2: Outcomes Without a Clear Mechanism (Radial Mortality Benefit, Aspirin/Ticagrelor Interaction, and More)

Presenter: Robert A. Byrne, Gregg W. Stone, Robert A. Harrington

October 30, 2017

Presentation TCT 2017

Topic 1: How Should We Evaluate Technologies in Their Infancy? TAVR, Renal Denervation, BVS, LAA Closure, Mechanical Circulatory Support, and More

Presenter: Robert A. Byrne, Gregg W. Stone, Aaron V. Kaplan

October 30, 2017

Presentation TCT 2017

Keynote Lecture: A Brief 40-Year History of PCI - How Far We've Come, How Far We Have to Go

Presenter: Dean J. Kereiakes, Spencer B. King III, Robert A. Byrne

October 30, 2017

Presentation TCT 2017

LAA Closure: Underused Therapy in Patients With High Bleeding Risk

Presenter: David Hildick-Smith, Lars Sondergaard, Robert A. Byrne

October 29, 2017

News Conference News TCT 2016

‘Worrisome’ 3-Year Data From ABSORB II Raise Concerns About First-Generation Bioresorbable Stent

Michael O'Riordan

October 30, 2016

Presentation TCT 2015

ISAR-DESIRE 4: A Prospective Randomized Trial of Plaque Modification With a Scoring Balloon During Drug-Coated Balloon Treatment of Coronary In-Stent Restenosis

Presenter: Cindy L. Grines, Robert A. Byrne

October 14, 2015

Presentation TCT 2015

ISAR-DESIRE 4: A Prospective Randomized Trial of Plaque Modification With a Scoring Balloon During Drug-Coated Balloon Treatment of Coronary In-Stent Restenosis

Presenter: Robert A. Byrne

October 14, 2015

News Conference News TCT 2015

ISAR-DESIRE 4: Scoring Balloon Predilation Effective at 1 Year in Patients With DES Restenosis

October 14, 2015

Presentation TCT 2015

Case Presentation Before Second-Time Treatment: Recurrent DES Restenosis

Presenter: Robert A. Byrne, Stefan K. James, Wojtek Wojakowski

October 11, 2015

$The Resurrection of Historic Therapies for Refractory Restenosis: Vascular Brachytherapy, Atherectomy, and Beyond$

Presentation TCT 2015

The Resurrection of Historic Therapies for Refractory Restenosis: Vascular Brachytherapy, Atherectomy, and Beyond

Presenter: Robert A. Byrne, Stefan K. James, Paul S. Teirstein

October 11, 2015

Presentation TCT 2015

Drug-Eluting Stent Restenosis State of the Art: Causes, Evaluation, and Treatment

Presenter: Robert A. Byrne, Stefan K. James, Fernando Alfonso

October 11, 2015

Presentation TCT 2015

How Was the Case Treated

Presenter: Robert A. Byrne, Stefan K. James, Ehrin J. Armstrong

October 11, 2015

Presentation TCT 2015

Case Presentation Before Treatment: An Unexpected and Difficult to Treat Stent Thrombosis

Presenter: Robert A. Byrne, Stefan K. James, Ehrin J. Armstrong

October 11, 2015

Presentation TCT 2015

Are There Differences in the Outcomes of Early, Late, and Very Late Stent Thrombosis?

Presenter: Robert A. Byrne, Stefan K. James, Donald Cutlip

October 11, 2015

Presentation TCT 2015

New Insights Into Neoatherosclerosis as a Frequent Common Denominator of DES Failure

Presenter: Robert A. Byrne, Stefan K. James, Renu Virmani

October 11, 2015

Presentation TCT 2015

Stent Thrombosis Update: Causes, Predictors, Implications, and Treatment

Presenter: Robert A. Byrne, Stefan K. James

October 11, 2015

Presentation TCT 2015

Debate: Are Bioabsorbable Polymers Preferable to Durable Polymers for Efficacy, Safety, or Required DAPT Duration? Yes, Eliminating the Polymer to Leave Behind a Bare-Metal Stent Surface Is a Desirable and Clinically Meaningful Goal!

Presenter: Stephen G. Ellis, John A. Ormiston, Robert A. Byrne

October 11, 2015

Presentation TCT 2014

Are There Meaningful Differences in Vascular Responses Between the Different Classes of Metallic Stent Technologies?

Presenter: Robert A. Byrne, Didier Carrié, Giuseppe De Luca, Francesco Prati

September 15, 2014

Advertisement

Topic 4: At the Cusp of Diminishing Returns for CV Therapies - Personalized Approaches and New Frontiers

Topic 3: Chronic Total Occlusion PCI - What Level of Evidence Is Required for Widespread Acceptance: Hard Endpoints vs QOL Measures

Topic 2: Outcomes Without a Clear Mechanism (Radial Mortality Benefit, Aspirin/Ticagrelor Interaction, and More)

Topic 1: How Should We Evaluate Technologies in Their Infancy? TAVR, Renal Denervation, BVS, LAA Closure, Mechanical Circulatory Support, and More

Keynote Lecture: A Brief 40-Year History of PCI - How Far We've Come, How Far We Have to Go

LAA Closure: Underused Therapy in Patients With High Bleeding Risk

‘Worrisome’ 3-Year Data From ABSORB II Raise Concerns About First-Generation Bioresorbable Stent

ISAR-DESIRE 4: A Prospective Randomized Trial of Plaque Modification With a Scoring Balloon During Drug-Coated Balloon Treatment of Coronary In-Stent Restenosis

ISAR-DESIRE 4: A Prospective Randomized Trial of Plaque Modification With a Scoring Balloon During Drug-Coated Balloon Treatment of Coronary In-Stent Restenosis

ISAR-DESIRE 4: Scoring Balloon Predilation Effective at 1 Year in Patients With DES Restenosis

Case Presentation Before Second-Time Treatment: Recurrent DES Restenosis

The Resurrection of Historic Therapies for Refractory Restenosis: Vascular Brachytherapy, Atherectomy, and Beyond

Drug-Eluting Stent Restenosis State of the Art: Causes, Evaluation, and Treatment

How Was the Case Treated

Case Presentation Before Treatment: An Unexpected and Difficult to Treat Stent Thrombosis

Are There Differences in the Outcomes of Early, Late, and Very Late Stent Thrombosis?

New Insights Into Neoatherosclerosis as a Frequent Common Denominator of DES Failure

Stent Thrombosis Update: Causes, Predictors, Implications, and Treatment

Debate: Are Bioabsorbable Polymers Preferable to Durable Polymers for Efficacy, Safety, or Required DAPT Duration? Yes, Eliminating the Polymer to Leave Behind a Bare-Metal Stent Surface Is a Desirable and Clinically Meaningful Goal!

Are There Meaningful Differences in Vascular Responses Between the Different Classes of Metallic Stent Technologies?

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content